Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.
Pfenex reported that Leidos Holdings (formerly SAIC) has awarded Pfenex a subcontract in support of the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and immune-enhancing adjuvant. The prime contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to improve the efficacy of both anthrax and West Nile virus vaccines by formulating them with a novel adjuvant that stimulates immune responses. Under the subcontract with Leidos, Pfenex will provide its rPA, which will be evaluated in various formulations with a selected adjuvant, to optimize the breadth and longevity of immune responses generated against anthrax.
This is the third government-funded contract awarded to Pfenex for the development of an anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology.
Source: Pfenex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.